Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The company is headquartered in Cambridge, Massachusetts and currently employs 5,800 full-time employees. The company went IPO on 2018-12-07. The firm is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). The company is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).
Follow-Up Questions
Moderna Inc의 CEO는 누구입니까?
Mr. Stephane Bancel은 2011부터 회사에 합류한 Moderna Inc의 Chief Executive Officer입니다.
MRNA 주식의 가격 성능은 어떻습니까?
MRNA의 현재 가격은 $27.18이며, 전 거래일에 increased 0.09% 하였습니다.
Moderna Inc의 주요 사업 주제나 업종은 무엇입니까?
Moderna Inc은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
Moderna Inc의 시가총액은 얼마입니까?
Moderna Inc의 현재 시가총액은 $10.5B입니다
Moderna Inc는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 23명의 분석가가 Moderna Inc에 대한 분석 평가를 실시했으며, 이는 0명의 강력한 매수, 4명의 매수, 19명의 보유, 4명의 매도, 그리고 0명의 강력한 매도를 포함합니다
